Jason Silvers - 26 Feb 2026 Form 4 Insider Report for Generate Biomedicines, Inc. (GENB)

Role
President & CFO
Signature
/s/ Michael Wolf, Attorney-in-Fact
Issuer symbol
GENB
Transactions as of
26 Feb 2026
Net transactions value
+$32,000
Form type
4
Filing time
02 Mar 2026, 17:54:42 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Silvers Jason President & CFO GENERATE BIOMEDICINES, INC., 101 SOUTH STREET, SUITE 900, SOMERVILLE /s/ Michael Wolf, Attorney-in-Fact 02 Mar 2026 0002109011

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GENB Common Stock Purchase $8,000 +500 $16.00 500 02 Mar 2026 By daughter
transaction GENB Common Stock Purchase $8,000 +500 $16.00 500 02 Mar 2026 By daughter
transaction GENB Common Stock Purchase $16,000 +1,000 $16.00 1,000 02 Mar 2026 By son

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GENB Stock Option (Right to Buy) Award $0 +295,608 $0.000000 295,608 26 Feb 2026 Common Stock 295,608 $16.00 Direct F1
transaction GENB Stock Option (Right to Buy) Award $0 +274,493 $0.000000 274,493 26 Feb 2026 Common Stock 274,493 $16.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option shall vest in two equal installments on each of February 19, 2029 and February 19, 2030, subject to the Reporting Person's continued service on each such vesting date.
F2 The shares underlying this option shall vest in forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.